Volume 3 Issue 1

Review Article: Cladribine in First Line and Relapsed Hairy Cell Leukemia and the Hairy Cell Leukemia Variant

Marlies Van Hoef1* and Xavier Troussard2

Hairy cell leukemia is a rare disease for which purine nucleoside analogues changed disease outcome. Pentostatin and 2-chorodeoxyadenosine (cladribine) have meanwhile been administered since over two decades. The former compound is available for intravenous administration and the latter for both intravenous and subcutaneous administration. Cladribine induces high response rates in first line purine nucleoside analog treatment, regardless of prior treatment with splenectomy, interferon or chemotherapy, and is also effective in relapsed disease. Literature describing the use of cladribine upfront and in later lines of treatment in hairy cell leukemia and the hairy cell leukemia variant is reviewed herein.
Keywords: Hairy cell leukemia (variant); Cladribine; Rituximab; First line; Relapsed

Cite this Article: Van Hoef M, Troussard X. Cladribine in First Line and Relapsed Hairy Cell Leukemia and the Hairy Cell Leukemia Variant. Int J Blood Dis Dis. 2019; 3(1): 001-007.

Published: 02 January 2019

Submit ManuscriptSubmit Special Issue

Authors submit all Proposals and manuscripts via Electronic Form!

All Journals

Creative Commons License Open Access by SciRes Literature is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at www.scireslit.com.